MUTANT HUMAN BETA-NEUROCYTE GROWTH FACTOR

• Main Authors: YOSHIKAWA KAZUHIDE, OTOMO REIKO
• Format: Patent
• Language: English
• Published: 10.07.1991
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PURPOSE:To improve the recovery of the subject substance by culturing a specific microorganism. CONSTITUTION:A microorganism (e.g. E.coli) containing a DNA coding a mutant human beta-neurocyte growth factor and transformed with a vector self- proliferative in a microorganism is cultured in a nutrient medium such as LB medium or M9-CA medium and the cells are separated. The mutant human beta-neurocyte growth factor has a structure corresponding to natural-type human beta-neurocyte growth factor provided that 4 cysteine residues in 6 cysteine residues excluding at least the 15- and 80-cysteine residues counted from the N-terminal are substituted with other amino acid residues. The culture liquid is purified by protein purification procedures such as salting out with ammonium sulfate, ultrafiltration and liquid chromatography to obtain the mutant human beta- neurocyte growth factor having the amino acid sequence of formula.